Portola Pharmaceuticals Inc (PTLA)

25.08
NASDAQ : Health Care
Prev Close 25.08
Day Low/High 0.00 / 0.00
52 Wk Low/High 15.68 / 38.04
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 56.54M
Market Cap 1.40B
EPS -4.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

First Week of PTLA February 2017 Options Trading

First Week of PTLA February 2017 Options Trading

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.

Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%

Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%

The most recent short interest data has been released for the 11/30/2016 settlement date, which shows a 693,347 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 5,883,540, an increase of 13.36% since 11/15/2016.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)

First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2017 expiration.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

First Week Of PTLA June 2017 Options Trading

First Week Of PTLA June 2017 Options Trading

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the June 2017 expiration.

Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients

Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients

If Approved, Betrixaban, an FDA Fast Track-Designated Therapy, Would Be First Anticoagulant for Hospital to Home Prevention of VTE in this High-Risk Patient Population

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

First Week of November 18th Options Trading For Portola Pharmaceuticals (PTLA)

First Week of November 18th Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the November 18th expiration.

Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass

Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.

How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress

Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress

Company to Host Webcast of Investor Event with Drs. Stuart J. Connolly and C. Michael Gibson to Discuss Data on Tuesday, August 30

October 21st Options Now Available For Portola Pharmaceuticals (PTLA)

October 21st Options Now Available For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options become available today, for the October 21st expiration.